Kymera Therapeutics, Inc.

KYMRNASDAQ

Market cap9.68B USDAs of Sep 22, 2026

Healthcare· Biotechnology· US

$117.67

Session change unavailable

Market closed · NASDAQ

Status checked Oct 25, 2026, 12:42 AM · America/New_York

Observed Sep 21, 2026, 8:00 PM UTC · Last available price

Kymera Therapeutics, Inc. (KYMR)

Loading market observation…

Research downloads are available with Pro.

Financial Metrics vs. Sector

Upgrade to Plus or Pro to explore this analysis.

Explore plans

Dated financials

As of Sep 22, 2026 · 42 of 48 observations available. Each value retains its reporting period. Trailing 12 months and fiscal-year earnings are separate measures. Financial observations and company disclosures retain their own dates. An observation date is not a filing publication date.

Price and valuation

Closing price was observed on Sep 21, 2026 (as of snapshot date Sep 22, 2026). Financial reporting periods are shown with each observation.

Closing price: 117.67 USD/shares; At Sep 21, 2026; Provider observation · observed Sep 22, 2026
Market capitalization: 9.68B USD; At Sep 21, 2026; Provider observation · observed Sep 22, 2026
Free cash flow yield: -2.46%; Provider TTM · observed Sep 22, 2026

Compare within the sector

Price to book is particularly useful for financial companies. Price to sales can support comparisons when earnings are negative.

Price to sales: 92.19x; Provider TTM · observed Sep 22, 2026
Price to book: 7.65x; Provider TTM · observed Sep 22, 2026

Additional valuation measures

Fiscal-year P/E uses the last completed financial year. Earnings yield expresses earnings relative to price as a percentage.

Financial statements and ratios

Company disclosures

Revenue · quarter: 65M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Gross profit · quarter: 65M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Operating income · quarter: -75.61M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Net income · quarter: -61.21M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Diluted EPS · quarter: -0.62 USD/shares; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Operating cash flow · quarter: -54.07M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Capital expenditure · quarter: 473,000 USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026
Free cash flow · quarter: -54.54M USD; At Jun 30, 2026; Provider quarter · observed Sep 21, 2026

View dated valuation comparison

Research snapshot

Loading research…